← FDA DRUG APPROVALS

FDA ANDA · ANDA208446

ABIRATERONE ACETATE

Sponsor: MYLAN

APPLICATION
ANDA208446
TYPE
ANDA
ORIGINAL APPROVAL
2018-10-31
LATEST ACTION
2025-05-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ABIRATERONE ACETATEPrescription
ABIRATERONE ACETATE 500MG · TABLET · ORAL
ABIRATERONE ACETATEPrescription
ABIRATERONE ACETATE 250MG · TABLET · ORAL

Approval history

2025-05-19Manufacturing (CMC) · Supplement 14 · unknownAP
2022-08-31Labeling · Supplement 9 · standardAP
2022-08-31Labeling · Supplement 6 · standardAP
2020-12-14Manufacturing (CMC) · Supplement 4 · unknownAP
2019-11-01Labeling · Supplement 3 · standardAP
2018-10-31UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →